The news immediately propelled Sage's stock, rocketing it past previous highs to $169.58. Cowen thinks there’s still upside.
Cowen analyst Ritu Baral maintained an Outperform rating on Sage and raised his price target from $135 to $202.
The treatment demonstrated statistical significance within 12 hours, sustained efficacy for four weeks, and met primary endpoints with “impressive, rapid, durable effectiveness.”
It also showed a positive safety profile with broad tolerance and common adverse effects. Previous concerns about elevated sedation levels were largely mitigated by night-time dosing and an altered capsule formulation.
“With a unique mechanism, superior efficacy, faster onset and good tolerability (as well potential benefits on sleep) compared to SSRIs, '217 can potentially become the first-line treatment for MDD with a potential for premium pricing to even branded SSRIs,” Baral wrote, noting that the program is ready for Phase 3.
Baral expects regulatory approval particularly considering the indication’s fast-track designation and Sage’s plan to pursue breakthrough designation. She anticipates peak MDD sales of $1.5 billion with potential additional sales for Parkinson’s and Essential tremor.
At time of publication, Sage was trading up 76.5 percent at a rate of $162.22.
Michael Phelps Opens Up About Struggles With ADHD, Depression: I Was Constantly Bouncing Off The Wall As A Kid
Phelps Talks Mental Health Awareness, Medibio's Algorithmic Diagnosis
Latest Ratings for SAGE
|Nov 2017||BMO Capital||Maintains||Outperform|
|Nov 2017||Bank of America||Maintains||Buy|
|Nov 2017||Canaccord Genuity||Maintains||Buy|
View More Analyst Ratings for SAGE
View the Latest Analyst Ratings
See more from Benzinga
- Why Broadcom Is A Favorite At Bernstein, With Or Without Qualcomm
- Here's What Sent Lending Club Shares Lower
- Yelp Gets Nailed With A Bad Review: Piper Jaffray Downgrades
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.